Yingying Guo Selected Research

Yingying Guo Research Topics

Disease

16	Neoplasms (Cancer) 06/2022 - 03/2013
4	Carcinogenesis 01/2022 - 06/2014
4	Infections 01/2022 - 03/2015
4	COVID-19 12/2021 - 01/2020
4	Breast Neoplasms (Breast Cancer) 04/2021 - 02/2012
3	Cardiomegaly (Heart Hypertrophy) 01/2022 - 01/2017
3	Hepatocellular Carcinoma (Hepatoma) 11/2015 - 02/2015
2	Hypoxia (Hypoxemia) 02/2022 - 01/2022
2	Esophageal Neoplasms (Esophageal Cancer) 01/2022 - 01/2020
2	Fibrosis (Cirrhosis) 10/2021 - 10/2021
2	Pulmonary Fibrosis (Fibrosing Alveolitis) 10/2021 - 01/2019
2	Drug-Related Side Effects and Adverse Reactions 04/2021 - 01/2020
2	Hypertension (High Blood Pressure) 01/2021 - 02/2015
2	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 03/2019
2	Adenocarcinoma 04/2016 - 06/2014
2	Osteoporosis 01/2016 - 07/2006
1	Shock 10/2022
1	Idiopathic Pulmonary Fibrosis 06/2022
1	Gastroenteritis 01/2022
1	Abdominal Obesity 01/2022
1	Azoospermia 01/2022
1	Chronic Disease (Chronic Diseases) 01/2022
1	Hypertrophy 01/2022
1	Esophageal Squamous Cell Carcinoma 01/2022
1	Hyperlipoproteinemia Type IV (Type IV, Hyperlipoproteinemia) 01/2022
1	Type III Amelogenesis Imperfecta 05/2021
1	Weight Loss (Weight Reduction) 01/2021
1	Obesity 01/2021
1	Prostatic Neoplasms (Prostate Cancer) 12/2020
1	Heart Failure 11/2020
1	Aneuploidy (Aneuploid) 09/2020
1	Necrosis 01/2020
1	Triple Negative Breast Neoplasms 01/2020
1	Pulmonary Arterial Hypertension 01/2020
1	Asthma (Bronchial Asthma) 01/2020
1	Disease Progression 01/2020

Drug/Important Bio-Agent (IBA)

12	Proteins (Proteins, Gene)FDA Link 06/2022 - 11/2015
9	Pharmaceutical PreparationsIBA 02/2022 - 07/2006
5	EnzymesIBA 01/2020 - 07/2006
4	Long Noncoding RNAIBA 06/2022 - 01/2019
4	AntioxidantsIBA 01/2022 - 01/2018
3	VaccinesIBA 01/2022 - 01/2012
3	Messenger RNA (mRNA)IBA 10/2021 - 01/2020
2	Biological ProductsIBA 01/2022 - 12/2020
2	Indicators and Reagents (Reagents)IBA 01/2022 - 01/2021
2	Bleomycin (Blenoxane)FDA LinkGeneric 10/2021 - 01/2019
2	Therapeutic UsesIBA 04/2021 - 01/2020
2	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2021 - 01/2017
2	LipidsIBA 01/2021 - 06/2017
2	Monoclonal AntibodiesIBA 01/2021 - 01/2020
2	LuciferasesIBA 12/2020 - 01/2020
2	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 01/2020 - 10/2015
2	GinsenosidesIBA 01/2019 - 10/2012
2	Mucin-1 (CA 15-3 Antigen)IBA 04/2016 - 11/2015
2	Transforming Growth Factor beta (TGF-beta)IBA 03/2015 - 02/2015
2	Glycoproteins (Glycoprotein)IBA 02/2015 - 06/2014
1	SNARE Proteins (SNAREs)IBA 10/2022
1	Immune Checkpoint InhibitorsIBA 06/2022
1	Hemoglobins (Hemoglobin)IBA 02/2022
1	diosmetinIBA 01/2022
1	AntibodiesIBA 01/2022
1	nitrosobenzylmethylamineIBA 01/2022
1	Broadly Neutralizing AntibodiesIBA 01/2022
1	Triglycerides (Triacylglycerol)IBA 01/2022
1	astaxanthine (astaxanthin)IBA 01/2022
1	CollagenIBA 10/2021
1	Protein Isoforms (Isoforms)IBA 10/2021
1	Nonsense Codon (Nonsense Mutation)IBA 05/2021
1	Silicon Dioxide (Silica)FDA LinkGeneric 04/2021
1	Hyaluronic Acid (Hyaluronan)IBA 04/2021
1	Neutralizing AntibodiesIBA 01/2021
1	SesquiterpenesIBA 12/2020
1	LactonesIBA 12/2020
1	oligomycin sensitivity-conferring protein (complex V)IBA 11/2020
1	InterferonsIBA 10/2020
1	CamptothecinIBA 09/2020
1	lanabecestatIBA 01/2020
1	Cytochrome P-450 CYP2C9IBA 01/2020
1	sinigrinIBA 01/2020
1	PhytochemicalsIBA 01/2020
1	Rosuvastatin Calcium (Crestor)FDA Link 01/2020
1	Cytochrome P-450 CYP3AIBA 01/2020
1	Transforming Growth Factor-beta Type I ReceptorIBA 01/2020
1	abemaciclibIBA 01/2020
1	Angiotensin-Converting Enzyme 2IBA 01/2020
1	Amyloid (Amyloid Fibrils)IBA 01/2020
1	Cytochrome P-450 CYP1A2 (CYP1A2)IBA 01/2020
1	MonocrotalineIBA 01/2020
1	Caffeine (No Doz)FDA LinkGeneric 01/2020
1	NF-kappa B (NF-kB)IBA 01/2020
1	Warfarin (Coumadin)FDA LinkGeneric 01/2020
1	Dextromethorphan (Racemethorphan)FDA LinkGeneric 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2020

Therapy/Procedure

9	Therapeutics 06/2022 - 02/2015
2	Drug Therapy (Chemotherapy) 04/2021 - 01/2020
1	Oncolytic Virotherapy 06/2022
1	Chemoprevention 01/2022
1	Tissue Transplantation 01/2022
1	Photothermal Therapy 04/2021
1	Combination Drug Therapy (Combination Chemotherapy) 01/2020